title: Lapatinib or trastuzumab in combination with an aromatase inhibitor for first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2.
authors.forename: Sally
authors.initials: S
authors.lastname: Doss
authors.forename: Janet
authors.initials: J
authors.lastname: Robertson
authors.forename: Jane
authors.initials: J
authors.lastname: Adam
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000008:administration & dosage; D014408:Biomarkers, Tumor / Q000037:antagonists & inhibitors* / Q000378:metabolism; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000378:metabolism / Q000401:mortality / Q000556:secondary; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D005260:Female; D019983:Guideline Adherence; D006801:Humans; D000077341:Lapatinib; D017410:Practice Guidelines as Topic; D019057:Quality-Adjusted Life Years; D011799:Quinazolines / Q000008:administration & dosage; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000068878:Trastuzumab; D016896:Treatment Outcome; D006113:United Kingdom; D015854:Up-Regulation
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D047072:Aromatase Inhibitors; D014408:Biomarkers, Tumor; D000077341:Lapatinib; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human